Literature DB >> 15083783

A quality-of-life study in high-risk (thickness > = or 2 mm) cutaneous melanoma patients in a randomized trial of 1-cm versus 3-cm surgical excision margins.

Julia A Newton-Bishop1, Clarissa Nolan, Faye Turner, Margaret McCabe, Candida Boxer, J Meirion Thomas, Gill Coombes, Roger P A'Hern, Jennifer H Barrett.   

Abstract

A quality-of-life study was carried out to test the hypothesis that melanoma patients treated with a 3-cm margin of excision suffer greater impairment of their quality of life than those treated with a 1-cm margin. The secondary aim was to determine the predictors of a poor patient perception of their excision scar. A postal questionnaire study was carried out using Hospital Anxiety and Depression (HAD), Psychosocial Adjustment of Illness Scale-Self-Report (PAIS-SR), Medical Outcomes Survey-Short Form 36 (MOS-SF36), and the Cassileth Scar questionnaires. Data were collected from 426 of the 537 patients who were mailed the questionnaires (response rate 79%). Fourteen percent had clinically significant anxiety and 5% had significant depression. A poor attitude toward quality of health care was associated with youth. Patients treated with a 3-cm margin excision had significantly poorer mental and physical function 1 mo after surgery, which disappeared within 6 mo. The greater difficulties experienced by the 3-cm margin group were particularly in their domestic, sexual, and social roles. Women, younger patients, those with poor physical and mental function after surgery, and those treated by a 3-cm margin were more likely to report a poorer perception of their scar. The poorer scar perception of patients in the 3-cm group persisted throughout the study period. Use of a 3-cm margin of excision for melanoma is associated with significantly more morbidity than use of a 1-cm margin, but this effect disappears in 6 mo. Patients treated by 3-cm excision were more likely, however, to have a persistent poor view of their scar. Youth and being female were also predictors of poor perception of the scar.

Entities:  

Mesh:

Year:  2004        PMID: 15083783     DOI: 10.1046/j.1087-0024.2003.09118.x

Source DB:  PubMed          Journal:  J Investig Dermatol Symp Proc        ISSN: 1087-0024


  11 in total

Review 1.  Quality of life assessment in surgical oncology trials.

Authors:  Kerry Avery; Jane M Blazeby
Journal:  World J Surg       Date:  2006-07       Impact factor: 3.352

Review 2.  [Psycho-oncological aspects of malignant melanoma. A systematic review from 1990-2008].

Authors:  M E Beutel; M Blettner; S Fischbeck; C Loquay; A Werner; H Marian
Journal:  Hautarzt       Date:  2009-09       Impact factor: 0.751

3.  Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study.

Authors:  D Schadendorf; M M Amonkar; M Milhem; K Grotzinger; L V Demidov; P Rutkowski; C Garbe; R Dummer; J C Hassel; P Wolter; P Mohr; U Trefzer; C Lefeuvre-Plesse; A Rutten; N Steven; G Ullenhag; L Sherman; F S Wu; K Patel; M Casey; C Robert
Journal:  Ann Oncol       Date:  2014-02-06       Impact factor: 32.976

Review 4.  Patient-Reported Physical Function Measures in Cancer Clinical Trials.

Authors:  Thomas M Atkinson; Angela M Stover; Daniel F Storfer; Rebecca M Saracino; Thomas A D'Agostino; Denise Pergolizzi; Konstantina Matsoukas; Yuelin Li; Ethan Basch
Journal:  Epidemiol Rev       Date:  2017-01-01       Impact factor: 6.222

Review 5.  Surgical Management of Melanoma: Advances and Updates.

Authors:  Juan A Santamaria-Barria; Joshua M V Mammen
Journal:  Curr Oncol Rep       Date:  2022-06-03       Impact factor: 5.075

6.  Illness-related distress in women with clinically localized cutaneous melanoma.

Authors:  Thomas M Atkinson; Nikki S Noce; Jennifer Hay; Brian T Rafferty; Mary S Brady
Journal:  Ann Surg Oncol       Date:  2012-09-11       Impact factor: 5.344

7.  Comparison of the Skin Cancer Quality of Life Impact Tool and the Skin Cancer Index Questionnaire in Measurement of Health-Related Quality of Life and the Effect of Patient Education Brochures in Patients with Actinic Keratosis, Non-melanoma, and Cutaneous Melanoma.

Authors:  Sam El Abbadi; Laura Susok; Egger Stockfleth; Falk Georges Bechara; Thilo Gambichler; Swetlana Herbrandt; Lisa Goldschmidtböing; Michael Sand
Journal:  Dermatol Ther (Heidelb)       Date:  2021-04-13

8.  1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study.

Authors:  Marc D Moncrieff; David Gyorki; Robyn Saw; Andrew J Spillane; John F Thompson; Howard Peach; Deemesh Oudit; Jenny Geh; Peter Dziewulski; Ewan Wilson; Paolo Matteucci; Rowan Pritchard-Jones; Roger Olofsson Bagge; Frances C Wright; Nic Crampton; Oliver Cassell; Navid Jallali; Adam Berger; John Kelly; Stephen Hamilton; Amer Durrani; Serigne Lo; Elizabeth Paton; Michael A Henderson
Journal:  Ann Surg Oncol       Date:  2018-05-30       Impact factor: 5.344

Review 9.  A systematic review of health-related quality of life in cutaneous melanoma.

Authors:  D Cornish; C Holterhues; L V van de Poll-Franse; J W Coebergh; T Nijsten
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

10.  Screening for distress in routine oncological care-a survey in 520 melanoma patients.

Authors:  Carmen Loquai; Vera Scheurich; Nils Syring; Irene Schmidtmann; Stephan Rietz; Andreas Werner; Stephan Grabbe; Manfred E Beutel
Journal:  PLoS One       Date:  2013-07-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.